Compound Evidence File
#EC-2026-0138
Liraglutide
Filed under Peptides. The bureau holds 155 laboratory returns for this compound from 59 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
59 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 9.9 | 10.0 | 17 Jan 2026 | 10 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 10.0 | 10.0 | 19 Mar 2026 | 24 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 10.0 | 9.9 | 10.0 | 16 Mar 2026 | 8 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 10.0 | 10.0 | 7 May 2026 | 11 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Apr 2026 | 17 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 10.0 | 9.9 | 10.0 | 20 May 2026 | 23 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 10.0 | 10.0 | 10.0 | 26 Dec 2025 | 6 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 10.0 | 10.0 | 10.0 | 1 Jun 2026 | 11 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 10.0 | 10.0 | 10.0 | 9 Jun 2026 | 16 Jun 2026 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 10.0 | 10.0 | 10.0 | 9 Jun 2025 | 9 Jun 2025 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Jan 2026 | 1 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 13 Jan 2026 | 9 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Jan 2026 | 15 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 28 Dec 2025 | 5 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 28 Dec 2025 | 22 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 4 | 9.9 | 9.9 | 10.0 | 11 Apr 2026 | 5 Aug 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 12 May 2026 | 7 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 9.9 | 9.9 | 10.0 | 11 Jul 2026 | 18 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 9.9 | 9.9 | 9.9 | 7 Mar 2026 | 12 Aug 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 9.9 | 15 May 2026 | 2 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 19 May 2026 | 6 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Jun 2026 | 28 Jun 2026 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 9.4 | 9.4 | 9.4 | 21 May 2025 | 21 May 2025 |
| Hunan Ruiwang Technology CenterCASE #VI-2026-0027 | X | 1 | 9.4 | 9.4 | 9.4 | 7 May 2025 | 7 May 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 9.0 | 7.4 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 5 | 8.8 | 7.7 | 10.0 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 8.7 | 7.5 | 9.6 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.2 | 7.1 | 8.9 | 21 May 2026 | 21 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 8.2 | 7.6 | 8.9 | 24 May 2026 | 24 May 2026 |
| Skye PeptidesCASE #VI-2026-0451 | X | 4 | 8.1 | 6.9 | 8.9 | 27 Feb 2025 | 26 Jan 2026 |
| Xianhong Tong XHT PeptidesCASE #VI-2026-0997 | X | 1 | 8.0 | 8.0 | 8.0 | 9 Jun 2025 | 9 Jun 2025 |
| PeptiSlimCASE #VI-2026-0557 | X | 3 | 7.9 | 6.5 | 9.8 | 24 Apr 2025 | 23 May 2026 |
| OupeptideCASE #VI-2026-0435 | X | 6 | 7.8 | 5.7 | 10.0 | 21 May 2025 | 25 May 2026 |
| Zhejiang Yichenkang BiotechnologyCASE #VI-2026-0269 | X | 1 | 7.8 | 7.8 | 7.8 | 2 Jul 2025 | 2 Jul 2025 |
| Verified PeptidesCASE #VI-2026-0407 | X | 1 | 7.8 | 7.8 | 7.8 | 27 Feb 2025 | 27 Feb 2025 |
| Dankang BioHealthCASE #VI-2026-0775 | X | 1 | 7.7 | 7.7 | 7.7 | 20 Jun 2025 | 20 Jun 2025 |
| Shandong Aishi BiotechnologyCASE #VI-2026-0308 | X | 1 | 7.6 | 7.6 | 7.6 | 3 Jun 2025 | 3 Jun 2025 |
| Bulk Peptide WholesaleCASE #VI-2026-0319 | X | 1 | 7.5 | 7.5 | 7.5 | 13 Jun 2025 | 13 Jun 2025 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 9 | 7.4 | 6.5 | 8.7 | 13 Feb 2025 | 23 May 2026 |
| ZZQ PeptidesCASE #VI-2026-0550 | E | 2 | 7.1 | 5.3 | 8.9 | 8 Jul 2025 | 19 Jan 2026 |
| Zztai PeptideCASE #VI-2026-0192 | C | 2 | 7.0 | 6.4 | 7.5 | 2 Jul 2025 | 20 May 2026 |
| Peptronix Bio PTBCASE #VI-2026-0979 | X | 1 | 7.0 | 7.0 | 7.0 | 6 May 2025 | 6 May 2025 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 6.8 | 6.8 | 6.8 | 2 Apr 2025 | 2 Apr 2025 |
| Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 | X | 1 | 6.7 | 6.7 | 6.7 | 27 Feb 2025 | 27 Feb 2025 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 6.4 | 6.4 | 6.4 | 7 May 2025 | 7 May 2025 |
| Lisa BiopeptideCASE #VI-2026-0131 | X | 1 | 6.2 | 6.2 | 6.2 | 2 Jul 2025 | 2 Jul 2025 |
| Pure RawzCASE #VI-2026-0767 | X | 1 | 6.1 | 6.1 | 6.1 | 3 Jun 2025 | 3 Jun 2025 |
| SRY LabsCASE #VI-2026-0657 | X | 4 | 6.0 | 4.9 | 7.4 | 3 Jul 2025 | 24 May 2026 |
| Liberty PeptidesCASE #VI-2026-0416 | X | 1 | 5.8 | 5.8 | 5.8 | 24 Apr 2025 | 24 Apr 2025 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 5.7 | 5.7 | 5.7 | 3 Jul 2025 | 3 Jul 2025 |
| Amino AmigosCASE #VI-2026-0061 | X | 1 | 5.6 | 5.6 | 5.6 | 3 Jul 2025 | 3 Jul 2025 |
| Accelerate LabsCASE #VI-2026-0686 | X | 1 | 5.4 | 5.4 | 5.4 | 17 Dec 2024 | 17 Dec 2024 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 5.1 | 5.1 | 5.1 | 20 Jun 2025 | 20 Jun 2025 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 5.1 | 5.1 | 5.1 | 11 Jun 2025 | 11 Jun 2025 |
| Modern AminosCASE #VI-2026-0635 | X | 1 | 4.2 | 4.2 | 4.2 | 8 Jul 2025 | 8 Jul 2025 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.0 | 0.0 | 0.0 | 28 Mar 2025 | 28 Mar 2025 |
| Weifang Xingbei International TradeCASE #VI-2026-0766 | X | 1 | 0.0 | 0.0 | 0.0 | 2 Apr 2025 | 2 Apr 2025 |
Open any subject to view the batch-level evidence for Liraglutide alone.